Sign-ups for Medicare’s GLP-1 coverage plan keep expanding, and Eli Lilly is dominating the market with 70% share, the company’s CEO David Ricks said.
They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.